71 West Capital Partners Buys Shares of 1,651 Stryker Corporation $SYK

71 West Capital Partners bought a new stake in Stryker Corporation (NYSE:SYK) in the 4th quarter, Holdings Channel.com reports. The fund bought 1,651 shares of the medical technology company’s stock, valued at approximately $580,000.

Other large investors have also recently bought and sold shares of the company. Faithward Advisors LLC lifted its stake in Stryker by 2.5% in the fourth quarter. Faithward Advisors LLC now owns 2,024 shares of the medical technology company’s stock valued at $711,000 after buying an additional 50 shares in the last quarter. Sienna Gestion bought a new position in Stryker in the fourth quarter valued at approximately $1,749,000. TritonPoint Partners LLC bought a new position in Stryker in the fourth quarter valued at approximately $509,000. USS Investment Management Ltd lifted its stake in Stryker by 5.6% in the fourth quarter. USS Investment Management Ltd now owns 60,357 shares of the medical technology company’s stock valued at $21,214,000 after buying an additional 3,183 shares in the last quarter. Finally, Venture Visionary Partners LLC lifted its stake in Stryker by 9.9% in the fourth quarter. Venture Visionary Partners LLC now owns 6,351 shares of the medical technology company’s stock valued at $2,340,000 after buying an additional 572 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

SYK has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Canaccord Genuity Group cut their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Truist Financial reiterated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Leerink Partners lowered their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Finally, BTIG Research lowered their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by insiders.

Stryker Price Performance

NYSE:SYK opened at $310.71 on Wednesday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a market cap of $119.11 billion, a P/E ratio of 35.96, a P/E/G ratio of 1.97 and a beta of 0.78. The firm’s fifty day moving average price is $315.51 and its two-hundred day moving average price is $342.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.